Amgen Inc. | StockChase
92
Amgen Inc. (AMGN-Q)

Last Price Recorded: $177.0400 on 2017-12-15

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical
92
Amgen Inc. (AMGN-Q)

Last Price Recorded: $177.0400 on 2017-12-15

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Amgen Inc.


Signal Opinion Expert
COMMENT
Amgen Inc.(AMGN-Q) 

November 2, 2017

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

biotechnology/pharmaceutical

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

biotechnology/pharmaceutical
Paul Harris, CFA

Portfolio Manager and Partner, Avenue Investment Ma...

PricePrice
$172.410
Owned Owned
Yes

HOLD
Amgen Inc.(AMGN-Q) 

October 26, 2017

Sell?This company has a very high free cash flow yield and is very profitable. Have some drugs coming off patent, but biotech drugs generally survive the loss of patents because the drugs are hard to copy. Thinks you will be fine with this in the long run. 2.6% dividend yield.

biotechnology/pharmaceutical

Sell?This company has a very high free cash flow yield and is very profitable. Have some drugs coming off patent, but biotech drugs generally survive the loss of patents because the drugs are hard to copy. Thinks you will be fine with this in the long run. 2.6% dividend yield.

biotechnology/pharmaceutical
John Burke

CEO & CIO, Burke Financial Stra...

PricePrice
$176.520
Owned Owned
Unknown

HOLD
Amgen Inc.(AMGN-Q) 

October 10, 2017

Hold or Sell? Within biotech and picking a single name, this company would be the way to do it. They are more diversified. They’ve had a few good quarters in a row beating earnings, and are still only trading at 14-16 levels. Putting up pretty good growth. Now that we are more comfortable with interest rates not going to the moon, that takes off the risk, opening up the door to make this more investable.

biotechnology/pharmaceutical

Hold or Sell? Within biotech and picking a single name, this company would be the way to do it. They are more diversified. They’ve had a few good quarters in a row beating earnings, and are still only trading at 14-16 levels. Putting up pretty good growth. Now that we are more comfortable with interest rates not going to the moon, that takes off the risk, opening up the door to make this more investable.

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Manag...

PricePrice
$185.790
Owned Owned
Unknown

HOLD
Amgen Inc.(AMGN-Q) 

September 19, 2017

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.

biotechnology/pharmaceutical

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$186.320
Owned Owned
No

HOLD
Amgen Inc.(AMGN-Q) 

September 14, 2017

They create drugs similar to other bio-similar drugs.  The competitive threats in biologics are a little bit similar.  They got approval this morning for a biologic drug.  He would like to see them consolidate here.

biotechnology/pharmaceutical

They create drugs similar to other bio-similar drugs.  The competitive threats in biologics are a little bit similar.  They got approval this morning for a biologic drug.  He would like to see them consolidate here.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$189.440
Owned Owned
Unknown

COMMENT
Amgen Inc.(AMGN-Q) 

August 17, 2017

A fabulous company and has done very well, but their drugs are very mature and make up a very large piece of their total revenue and portfolio. They are spending a lot of money on R&D which has some promise, but no guarantee that they are going to be able to replace the revenue flow. The stock is trading at about 12X earnings. Prefers something that has more current opportunities and a deeper pipeline.

biotechnology/pharmaceutical

A fabulous company and has done very well, but their drugs are very mature and make up a very large piece of their total revenue and portfolio. They are spending a lot of money on R&D which has some promise, but no guarantee that they are going to be able to replace the revenue flow. The stock is trading at about 12X earnings. Prefers something that has more current opportunities and a deeper pipeline.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$167.810
Owned Owned
Unknown

COMMENT
Amgen Inc.(AMGN-Q) 

July 24, 2017

Trading range would be between $129 and about $180. Generally, he likes breakouts, but the chart shows that breakouts in the past have failed. He would be a little concerned with this.

biotechnology/pharmaceutical

Trading range would be between $129 and about $180. Generally, he likes breakouts, but the chart shows that breakouts in the past have failed. He would be a little concerned with this.

biotechnology/pharmaceutical
Keith Richards

Portfolio Manager, ValueTrend Wealth Ma...

PricePrice
$181.060
Owned Owned
Unknown

COMMENT
Amgen Inc.(AMGN-Q) 

June 9, 2017

He would advocate Gilead (GILD-Q) instead. It has one of the strongest hepatitis C franchises in the world. This stock is down 58% from its all-time high and trading at less than 9X earnings with a wonderful management team.

biotechnology/pharmaceutical

He would advocate Gilead (GILD-Q) instead. It has one of the strongest hepatitis C franchises in the world. This stock is down 58% from its all-time high and trading at less than 9X earnings with a wonderful management team.

biotechnology/pharmaceutical
David Dietze

Founder, Pres. & Chief Investment Strategist, Point View Wealth Ma...

PricePrice
$164.060
Owned Owned
Unknown

HOLD
Amgen Inc.(AMGN-Q) 

May 19, 2017

He likes this as an investment. It could be a core health care holding in any portfolio. They’ve generated tremendous cash flow and have a very strong balance sheet.

biotechnology/pharmaceutical

He likes this as an investment. It could be a core health care holding in any portfolio. They’ve generated tremendous cash flow and have a very strong balance sheet.

biotechnology/pharmaceutical
John Petrides

Managing Dir. & Portfolio Manager, Point View Wealth Ma...

PricePrice
$156.510
Owned Owned
Unknown

DON'T BUY
Amgen Inc.(AMGN-Q) 

May 17, 2017

To take out the idiosyncratic risk, he would play Biotechs through the ETF iShares NASDAQ BioTech (IBB-Q). They all have their individual pipelines, but ultimately are going to trade very similarly, except for idiosyncratic risk, which you want to avoid. He wouldn’t advocate buying Biotech or Pharma right now given the pricing pressure of the policy measures, etc.

biotechnology/pharmaceutical

To take out the idiosyncratic risk, he would play Biotechs through the ETF iShares NASDAQ BioTech (IBB-Q). They all have their individual pipelines, but ultimately are going to trade very similarly, except for idiosyncratic risk, which you want to avoid. He wouldn’t advocate buying Biotech or Pharma right now given the pricing pressure of the policy measures, etc.

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Manag...

PricePrice
$157.060
Owned Owned
Unknown

HOLD
Amgen Inc.(AMGN-Q) 

May 10, 2017

A larger cap pure play biotech company, that has a deep pipeline in bio-similars. He doesn’t see competition in the near term for their drug Enbrow (?), which is 3%-2.5% of their top line. They have some drugs that have come off patent, and need to backfill on the top line. One way they were looking to do this was through the PCSK9 drug, a cardio cholesterol lowering drug. Initially they came out with positive results. He bought a Put for some protection. A great balance sheet and an OK yield and modest growth. He is monitoring this. Rates it as a very strong Hold.

biotechnology/pharmaceutical

A larger cap pure play biotech company, that has a deep pipeline in bio-similars. He doesn’t see competition in the near term for their drug Enbrow (?), which is 3%-2.5% of their top line. They have some drugs that have come off patent, and need to backfill on the top line. One way they were looking to do this was through the PCSK9 drug, a cardio cholesterol lowering drug. Initially they came out with positive results. He bought a Put for some protection. A great balance sheet and an OK yield and modest growth. He is monitoring this. Rates it as a very strong Hold.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$160.510
Owned Owned
Yes

COMMENT
Amgen Inc.(AMGN-Q) 

April 13, 2017

A great company. It is considered a biotech company, but has a market cap of over $1 billion. Trading at only 13X earnings and has a great free cash flow yield of almost 12%. He feels their pipeline is really strong and that the value of the company is 20% higher than it is here.

biotechnology/pharmaceutical

A great company. It is considered a biotech company, but has a market cap of over $1 billion. Trading at only 13X earnings and has a great free cash flow yield of almost 12%. He feels their pipeline is really strong and that the value of the company is 20% higher than it is here.

biotechnology/pharmaceutical
Paul Harris, CFA

Portfolio Manager and Partner, Avenue Investment Ma...

PricePrice
$161.610
Owned Owned
Yes

TOP PICK
Amgen Inc.(AMGN-Q) 

March 7, 2017

This is cheap, trading at roughly 13X versus the S&P at 17.4X. It has a free cash flow yield of roughly 8% plus a pretty good dividend yield of 2.56%. It is going to grow its dividend probably in the 10%-15% range. The stock is undervalued and underloved. It has held up really well despite all the tweets and all the other things going on. It is a biotech company, but it is one of the best and certainly one of the biggest. (Analysts’ price target is $189.50.)

biotechnology/pharmaceutical

This is cheap, trading at roughly 13X versus the S&P at 17.4X. It has a free cash flow yield of roughly 8% plus a pretty good dividend yield of 2.56%. It is going to grow its dividend probably in the 10%-15% range. The stock is undervalued and underloved. It has held up really well despite all the tweets and all the other things going on. It is a biotech company, but it is one of the best and certainly one of the biggest. (Analysts’ price target is $189.50.)

biotechnology/pharmaceutical
John Stephenson

President & CEO, Stephenson & Company...

PricePrice
$177.380
Owned Owned
Yes

PAST TOP PICK
Amgen Inc.(AMGN-Q) 

February 22, 2017

(A Top Pick June 22/16. Up 17.47%.) He knew we were coming into some volatile times back in June, and this is one of the dominant biotech companies. Really likes their PCSK9 cholesterol drug, which is going to be a blockbuster.

biotechnology/pharmaceutical

(A Top Pick June 22/16. Up 17.47%.) He knew we were coming into some volatile times back in June, and this is one of the dominant biotech companies. Really likes their PCSK9 cholesterol drug, which is going to be a blockbuster.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$172.610
Owned Owned
Yes

BUY
Amgen Inc.(AMGN-Q) 

January 30, 2017

A health care stock that has been beaten up through the headlines.  It is cheap and she likes it.  It took a bigger hit than it should have.  There is more than 20% upside according to analysts.  They have quite a few drugs in phase III trials.

biotechnology/pharmaceutical

A health care stock that has been beaten up through the headlines.  It is cheap and she likes it.  It took a bigger hit than it should have.  There is more than 20% upside according to analysts.  They have quite a few drugs in phase III trials.

biotechnology/pharmaceutical
Erin Gibbs

V.P., S&P Global Market In...

PricePrice
$154.430
Owned Owned
Unknown

Showing 1 to 15 of 92 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.

Successfully Saved Company